RetaCalc
Protocol library
SingleNot ApprovedMixedVery Low confidenceSourced

BPC-157

An investigational gastric peptide fragment with extensive preclinical claims but extremely limited and uncontrolled human evidence across oral, local and intravenous routes.

Evidence context, not a personal protocol

Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.

Dosage and protocol evidence

Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.

Community GuideSubcutaneous in guideDaily
Third-party educational schedule for a 5 mg research vial

200 mcg daily in weeks 1-2, 400 mcg in weeks 3-4 and 600 mcg in weeks 5-8

The source describes a preclinical extrapolation. It is not a validated human dose, and published reviews do not establish a standard injectable regimen.

View source

Evidence summary

An investigational gastric peptide fragment with extensive preclinical claims but extremely limited and uncontrolled human evidence across oral, local and intravenous routes.

Protocol basis

The page is based on reviews that distinguish a large animal literature from a handful of uncontrolled human observations. That evidence does not support a standard oral or injectable schedule.

What remains uncertain

Pharmaceutical-grade formulation, human exposure-response, longer-term safety and controlled efficacy are all unresolved.

Warnings and contraindications

No approved BPC-157 formulation or validated dosing regimen exists.
Published human information involves fewer than 30 participants across uncontrolled pilots.
Route, purity, stability and pharmacokinetics cannot be inferred from animal experiments.